CN104334547B - 作为kv3抑制剂的三唑类 - Google Patents

作为kv3抑制剂的三唑类 Download PDF

Info

Publication number
CN104334547B
CN104334547B CN201380026338.8A CN201380026338A CN104334547B CN 104334547 B CN104334547 B CN 104334547B CN 201380026338 A CN201380026338 A CN 201380026338A CN 104334547 B CN104334547 B CN 104334547B
Authority
CN
China
Prior art keywords
methyl
alkyl
epoxide
phenyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380026338.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104334547A (zh
Inventor
A·马拉斯科
G·阿尔瓦罗
A·德科
D·汉普雷希特
P·丹布罗索
S·托马西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autifony Therapeutics Ltd
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1209020.5A external-priority patent/GB201209020D0/en
Priority claimed from GBGB1209019.7A external-priority patent/GB201209019D0/en
Priority claimed from GBGB1209013.0A external-priority patent/GB201209013D0/en
Priority claimed from GBGB1222393.9A external-priority patent/GB201222393D0/en
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of CN104334547A publication Critical patent/CN104334547A/zh
Application granted granted Critical
Publication of CN104334547B publication Critical patent/CN104334547B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/48Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of 2,2-dimethylcyclopropane rings, e.g. nitrile of chrysanthemumic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/257Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/29Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/30Compounds having groups
    • C07C43/313Compounds having groups containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76Benzo[c]pyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380026338.8A 2012-05-22 2013-05-22 作为kv3抑制剂的三唑类 Expired - Fee Related CN104334547B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB1209013.0 2012-05-22
GBGB1209020.5A GB201209020D0 (en) 2012-05-22 2012-05-22 Novel compounds
GB1209020.5 2012-05-22
GBGB1209019.7A GB201209019D0 (en) 2012-05-22 2012-05-22 Novel compounds
GB1209019.7 2012-05-22
GBGB1209013.0A GB201209013D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201261702337P 2012-09-18 2012-09-18
US61/702,337 2012-09-18
GBGB1222393.9A GB201222393D0 (en) 2012-12-12 2012-12-12 Novel compounds
GB1222393.9 2012-12-12
PCT/GB2013/051347 WO2013175215A1 (en) 2012-05-22 2013-05-22 Triazoles as kv3 inhibitors

Publications (2)

Publication Number Publication Date
CN104334547A CN104334547A (zh) 2015-02-04
CN104334547B true CN104334547B (zh) 2017-06-06

Family

ID=49623224

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380026338.8A Expired - Fee Related CN104334547B (zh) 2012-05-22 2013-05-22 作为kv3抑制剂的三唑类

Country Status (6)

Country Link
US (4) US9422252B2 (https=)
EP (1) EP2852589B1 (https=)
JP (1) JP6240667B2 (https=)
CN (1) CN104334547B (https=)
BR (1) BR112014028991A2 (https=)
WO (1) WO2013175215A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
CN103596943B (zh) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
MX2014013489A (es) * 2012-05-09 2015-02-12 Bayer Cropscience Ag 5-halogenopirazolindanil carboxamidas.
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US9669030B2 (en) * 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
US9556190B2 (en) 2013-12-20 2017-01-31 Merck Sharp & Dohme Corp. Piperidinyloxy lactone orexin receptor antagonists
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
EP3703675A4 (en) 2017-10-30 2021-06-16 Neuropore Therapies, Inc. SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES
US20210290597A1 (en) * 2018-06-20 2021-09-23 Neuropore Therapies, Inc. Method of treating a condition associated with neurodegeneration using inhibitors of oat3
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
KR102854594B1 (ko) 2018-10-16 2025-09-02 오티포니 세라피틱스 리미티드 신규한 화합물
AR116898A1 (es) * 2018-10-30 2021-06-23 H Lundbeck As DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3
MY210184A (en) * 2018-11-30 2025-08-31 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
BR112022013339A2 (pt) 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
KR20240046748A (ko) 2021-08-10 2024-04-09 오티포니 세라피틱스 리미티드 칼륨 채널 조절제
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097997A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
CN101600689A (zh) * 2006-12-15 2009-12-09 Irm责任有限公司 作为大麻素受体1活性抑制剂的化合物和组合物
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US6002016A (en) 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
US5607932A (en) * 1994-07-12 1997-03-04 Janssen Pharmaceutica N.V. Heterocyclic derivatives of azolones
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
MX9708802A (es) 1995-05-17 1998-02-28 Du Pont Amidas ciclicas fungicidas.
KR19990028230A (ko) 1995-06-20 1999-04-15 미리암 디. 메코너헤이 살절지동물성 및 살진균성 시클릭 아미드
BR9711816A (pt) 1996-08-01 1999-08-31 Du Pont Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes.
US5728834A (en) 1996-11-14 1998-03-17 Wyckoff Chemical Company, Inc. Process for preparation of 4-aryl-1,2,4-triazol-3-ones
EP0944314A1 (en) 1996-11-26 1999-09-29 E.I. Du Pont De Nemours And Company Methyl substituted fungicides and arthropodicides
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
AU6040398A (en) 1997-01-30 1998-08-25 E.I. Du Pont De Nemours And Company Fungicidal compositions
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 6−フルオロビシクロ[3.1.0]ヘキサン誘導体
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd 4−置換−2−アミノビシクロ[3.1.0]ヘキサン−2,6−ジカルボン酸誘導体及び製薬用組成物
WO2001007032A1 (en) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Th2 differentiation inhibitors
CN1431896A (zh) 2000-04-04 2003-07-23 盐野义制药株式会社 含有高脂溶性药物的油性组合物
FR2807434B1 (fr) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
AU2002354410A1 (en) 2001-12-05 2003-06-17 Japan Tobacco Inc. Triazole compound and medicinal use thereof
ATE403426T1 (de) 2002-02-07 2008-08-15 Univ Missouri Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
AU2003206021A1 (en) 2003-02-20 2004-09-09 Ranbaxy Laboratories Limited Derivatives of azasugars as anticancer agents
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
NZ548817A (en) * 2004-03-10 2009-04-30 Janssen Pharmaceutica Nv MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
AR052342A1 (es) 2004-12-21 2007-03-14 Janssen Pharmaceutica Nv Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
KR101456722B1 (ko) 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
KR20100014811A (ko) 2007-04-20 2010-02-11 데시페라 파마슈티칼스, 엘엘씨. 골수증식성 질환 및 기타 증식성 질환의 치료에 유용한 키나제 억제제
EP2356111A1 (en) 2008-11-10 2011-08-17 Schering Corporation Compounds for the treatment of inflammatory disorders
EP2379534A1 (en) 2008-12-22 2011-10-26 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2011073114A1 (en) 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2012037132A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
EA023768B1 (ru) * 2010-12-06 2016-07-29 Отифони Терапеутикс Лимитед ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
CN103596943B (zh) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
EP2788339B1 (en) 2011-12-06 2016-03-09 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
US9422252B2 (en) * 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101600689A (zh) * 2006-12-15 2009-12-09 Irm责任有限公司 作为大麻素受体1活性抑制剂的化合物和组合物
WO2009097997A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2011069951A1 (en) * 2009-12-11 2011-06-16 Glaxo Group Limited Imidazolidinedione derivatives

Also Published As

Publication number Publication date
US9422252B2 (en) 2016-08-23
US20150111910A1 (en) 2015-04-23
EP2852589A1 (en) 2015-04-01
US20190071405A1 (en) 2019-03-07
US20200172496A1 (en) 2020-06-04
EP2852589B1 (en) 2021-04-28
WO2013175215A1 (en) 2013-11-28
US10611735B2 (en) 2020-04-07
US20160318882A1 (en) 2016-11-03
JP6240667B2 (ja) 2017-11-29
CN104334547A (zh) 2015-02-04
US10160730B2 (en) 2018-12-25
JP2015520764A (ja) 2015-07-23
BR112014028991A2 (pt) 2017-06-27
US11180461B2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
CN104334547B (zh) 作为kv3抑制剂的三唑类
CN103596943B (zh) 用作kv3抑制剂的乙内酰脲衍生物
US11541052B2 (en) Compounds
CN103974944B (zh) 用作kv3抑制剂的乙内酰脲衍生物
KR20120107490A (ko) 이미다졸리딘디온 유도체
TWI827706B (zh) 新穎化合物
JP2019502696A (ja) Kv3チャネルのヒダントインモジュレーター
WO2013182850A1 (en) Isobenzofuran- 5 -yl-oxy- (hetero) aryl - imidazolidine - 2, 4 -dione derivatives modulators of kv3 potassium channels for the treatment of cns disorders.
CN117751119A (zh) 钾通道调节剂
JP7522203B2 (ja) Kv3モジュレーター
RU2830279C2 (ru) Новые соединения
HK40059039B (en) Novel compounds
HK40059039A (en) Novel compounds
EA049235B1 (ru) Модуляторы kv3
BR112014013400B1 (pt) Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil
HK1203072B (en) Hydantoin derivatives useful as kv3 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170606

Termination date: 20210522